EpistemisSynthesis and Summary of High Complexity Monitoring
To facilitate rapid memorization and precision clinical decision-making in obstetric or gynecological emergencies, a general diagnostic monitoring map is presented for each key pharmacological group.
File
| Representative Drug | Pharmacological Group | Primary Indication | Critical Safety Monitoring Criterion |
|---|---|---|---|
| Oxytocin | Uterotonic peptide | Induction of labor / PPH | Fetal heart rate (monitor decelerations), tachysystole and hourly diuresis (avoid water intoxication). |
| Carbetocin | Oxytocin analogue | Prevention of atony in cesarean section | Maternal blood pressure (monitor for sudden post-IV bolus hypotension) and basal uterine tone. |
| Misoprostol | Prostaglandin E1 | Cervical ripening / Abortion | Measurement of body temperature (common induction of transient fever > 38°C), secondary vaginal bleeding and dynamics of the myometrium. |
| Methylergometrine | Ergot alkaloid | Refractory PPH due to atony | Mandatory baseline blood pressure (absolutely contraindicated in preeclampsia and hypertensive patients). |
| Atosiban | OXTR antagonist | Tocolysis preterm labor | Membrane integrity (confirm absence of active chorioamnionitis before delaying delivery). |
| Nifedipine | Calcium blocker L | Tocolysis preterm birth | Maternal heart rate (compensatory tachycardia), BP (avoid hypotension) and diuresis. Contraindicated with simultaneous MgSO4. |
| Magnesium Sulfate | Calcium antagonist / NMDA | Prophylaxis of eclampsia / Fetus | Presence of patellar reflex, diuresis > 30 mL/h and RR 12-14 rpm. Antidote: Calcium Gluconate. |
| Indomethacin | COX-1 and 2 inhibitor | Tocolysis / Polyhydramnios | Gestational age limit < 32 weeks. Fetal Doppler monitoring of the ductus arteriosus and ILA after 48 hours of use. |
| Micronized Progesterone | Natural luteal hormone | Prevention of preterm birth | Weekly transvaginal cervical ultrasound evaluation and vaginal secretion of fatty residues. |
| Clomiphene Citrate | Central SERM | Ovulation induction | Control ovarian ultrasound to rule out functional cysts or unwanted massive multifollicular growth. |
| Follitropin Alfa / hCG | Gonadotropins | TRA / Controlled stimulation | Serum estradiol levels and daily weight of the patient (warning sign of early ascites due to OHSS). |
| Labetalol / Methyldopa | Antihypertensives | Gestational hypertension | Use of ACEI/ARB is prohibited. Control of maternal heart rate, cerebral sedation status (methyldopa) and liver profile. |
| Betamethasone / Dexamethasone | Glucocorticoids | Fetal lung maturation | Maternal fasting and postprandial blood glucose (causes transient hyperglycemia for 48 hours in diabetic pregnant women). |
"Excellence in obstetric-gynecological therapy lies in the rigorous balance between maternal pathophysiology and developmental embryology: curing the mother while guaranteeing the preservation of the fetus."
Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.
- System
- Gynecology and Obstetrics
- Cluster
- Integration and Clinical Review